Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00138177 · ClinicalTrials.gov registry record · Phase 1

Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Colon Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
54
Enrollment target
1
Study location

NCT00138177 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Colon Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 54 participants, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00138177, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Colon Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable colorectal cancer or solid tumor. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Conditions Studied

Unspecified Adult Solid Tumor, Protocol Specific Recurrent Colon Cancer Recurrent Rectal Cancer Stage III Colon Cancer Stage IV Colon Cancer Stage IV Rectal Cancer Stage III Rectal Cancer

Interventions

  • DRUG vorinostat
  • DRUG oxaliplatin
  • DRUG fluorouracil
  • DRUG leucovorin calcium

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2005-07
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00138177

The ClinicalTrials.gov registry entry for NCT00138177 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (89% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 4 interventions - of which vorinostat is the first listed.

NCT00138177 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00138177 about?

NCT00138177 is a clinical study titled "Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors". This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable colorectal cancer or solid tumor. Drugs used in chemotherapy, such as s...

What is the current status of trial NCT00138177?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2005-07.

What conditions does trial NCT00138177 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage IV Colon Cancer.

What interventions are being tested in trial NCT00138177?

The interventions under investigation include: vorinostat (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG).

Who is sponsoring clinical trial NCT00138177?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00138177 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

Recurrent Colon Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.